Category: Boulder/Denver

With Triage System, Companies See Toehold for A.I. in Radiology

This story is part of an ongoing Xconomy series on A.I. in healthcare. Other stories cover big-company efforts, a genomics hackathon, the impact on doctors and patients, and business models of A.I. in healthcare. Years ago, radiology underwent a radical transformation with the shift from film to widespread use of digital image displays. That set … Continue reading “With Triage System, Companies See Toehold for A.I. in Radiology”

5 Privacy Worries on 4 Wheels: Staying Safe in the Connected Car Era

As modern vehicles are upgraded to include Internet-enabled technologies designed to access, store, and transmit data for entertainment and safety purposes, consumers are presented with a double-edged sword. On one hand, these connected systems provide important convenience benefits for consumers, but on the flip side, motor vehicles are being exposed to a growing number of … Continue reading “5 Privacy Worries on 4 Wheels: Staying Safe in the Connected Car Era”

What’s the Business Model for Artificial Intelligence in Healthcare?

This story is part of an ongoing Xconomy series on A.I. in healthcare. Other stories cover big-company efforts, a genomics hackathon, and the impact on doctors and patients. These are heady times for using artificial intelligence to extract insights from healthcare data—in particular, from the tidal wave of information coming out of fields like genomics … Continue reading “What’s the Business Model for Artificial Intelligence in Healthcare?”

Bio Roundup: Senate Drama, A.I. Stories, Data Dives, Shkreli & More

There is no Obamacare replacement, at least not as of this writing. The Senate Republicans are fractured, with a handful of conservatives and moderates each giving a cold shoulder to their chamber’s version of healthcare reform, the Better Care Reconciliation Act. The nonpartisan Congressional Budget Office report Monday put the bill’s potential effects in stark … Continue reading “Bio Roundup: Senate Drama, A.I. Stories, Data Dives, Shkreli & More”

New Study: DNA Tests For Healthy People Have “Uncertain Value”

Genome sequencing is becoming more common for people diagnosed with cancer. Should it become part of a healthy person’s checkup, too? A new study published Monday in the Annals of Internal Medicine questions the practicality of making DNA tests standard for people who don’t have a cancer diagnosis or aren’t trying to identify a mysterious … Continue reading “New Study: DNA Tests For Healthy People Have “Uncertain Value””

U.S. IPOs Surge Amid Nettlesome Risks; Top 10 Deals So Far in 2017

[Updated 6/27/17 5:00 pm. See below.] Improving economic fundamentals are stoking the IPO pipeline in the United States and elsewhere, according to a report issued Tuesday by the global consultant and accounting firm EY. Eighty companies raised a total of $22 billion on U.S. exchanges during the first half of 2017, according to the report … Continue reading “U.S. IPOs Surge Amid Nettlesome Risks; Top 10 Deals So Far in 2017”

Boston Is Arguably the Heart of Biotech. But Who Makes It So? Have Your Say.

By the end of this year, for the first time, patients with certain deadly types of blood cancer might have a new option, CAR-T cell therapy, to prolong their life. Immunotherapy could further entrench itself as a mainstay of cancer treatment. Newer drugmaking methods—RNA interference and gene therapy—could get their first ever FDA reviews. Multiple … Continue reading “Boston Is Arguably the Heart of Biotech. But Who Makes It So? Have Your Say.”

Bio Roundup: Senate Trumpcare, FDA On Cancer, Alzheimer Review & More

All eyes are on the nation’s capital this week, where the Senate released its version of the American Health Care Act (now called the Better Care Reconciliation Act) and the White House worked on an executive order to address drug prices. No one knows how to pay for high-priced medicines that could bring long-term relief … Continue reading “Bio Roundup: Senate Trumpcare, FDA On Cancer, Alzheimer Review & More”

Mary Lou Jepsen: The Full Xconomy Voices Interview

For the inaugural episode of our new podcast, Xconomy Voices, we chose to speak with Bay Area entrepreneur and executive Mary Lou Jepsen. She leads a startup called Openwater, which is developing a new kind of wearable imaging device that might one day enable communication by thoughts alone. Of course, there are nearer-term goals as … Continue reading “Mary Lou Jepsen: The Full Xconomy Voices Interview”

Introducing Xconomy Voices (Podcast), Episode 1: Mary Lou Jepsen

It’s always been Xconomy’s mission to reach audiences—both here on our website, and at our many live events around the country—with deep insights into the innovation process, divined from experts embedded in the world’s most important hubs of high-tech entrepreneurship. And now we’re doing that in one more medium: podcasting. I’m thrilled to be collaborating … Continue reading “Introducing Xconomy Voices (Podcast), Episode 1: Mary Lou Jepsen”

Repare Nabs $68M To Find Synthetic Lethal Cancer Targets Beyond PARP

The concept of synthetic lethality has been around for decades, but only recently has it been exploited for cancer therapy. The idea is to hit cancer cells in at least two places at once; the trick is to find the right combination of genetic mutations that make the cells vulnerable. The newest company aiming to … Continue reading “Repare Nabs $68M To Find Synthetic Lethal Cancer Targets Beyond PARP”

Alzheimer’s Drug Pipeline Analysis: Have We Hit Peak Amyloid?

A 2014 report provided a stark frame of reference for the challenge of fighting Alzheimer’s disease, showing that 99.6 percent of all drugs in the field had failed in one way or another. Led by Jeffrey Cummings, director of the Cleveland Clinic’s Lou Ruvo Center for Brain Health, the same authors recently published a new … Continue reading “Alzheimer’s Drug Pipeline Analysis: Have We Hit Peak Amyloid?”

New Ovarian Cancer Data Suggests Larger Role For Top Clovis Drug

Clovis Oncology received a short-cut approval from the FDA last year for its ovarian cancer drug that treats women with the common BRCA genetic mutation. Clovis (NASDAQ: [[ticker:CLVS]]) said Monday it now has evidence that the drug, rucaparib (Rubaca), can treat a wider swath of patients, and it will ask the FDA for approval this … Continue reading “New Ovarian Cancer Data Suggests Larger Role For Top Clovis Drug”

Bio Roundup: Trumpcare Is Mean, SCOTUS Says Go, Merck’s Myeloma No

What exactly does the American Health Care Act, the Republican proposal to replace Obamacare, currently look like? Few people know, because the Senate version is being negotiated behind closed doors in Washington D.C. without any public hearings. We do know President Trump now thinks the version of the AHCA that squeaked through the House is … Continue reading “Bio Roundup: Trumpcare Is Mean, SCOTUS Says Go, Merck’s Myeloma No”

Patient Network Group Says Majority of Members Want To Keep Obamacare

A U.S. patient networking group called PatientsLikeMe has dipped its toe in the waters of public opinion, asking its members what they think of the healthcare policy fight. There are many caveats, but the numbers trend in the same direction that other national polls have found—a shift towards more acceptance of the Affordable Care Act, … Continue reading “Patient Network Group Says Majority of Members Want To Keep Obamacare”

Getting Women On Boards: Three Ways to Increase the Numbers

The hot topic of getting more qualified women on corporate boards continues unabated. Recent statistics show how companies with women prominently serving in such capacities experience higher-than-average financial performance. A major investment group even declared earlier this year that it would push to get women on the boards of the companies in their portfolio. Yet … Continue reading “Getting Women On Boards: Three Ways to Increase the Numbers”

Bio Roundup: ASCO Digested, Juliet Unveiled, PTC Slated & More

The New York Times Magazine wrote a few weeks ago about the extraordinary metabolic changes in a python after it gulps down a 50,000 calorie meal. The biomedical world was like a postprandial python this week; after extending its maw around the supersized meal of news and data from the American Society for Clinical Oncology … Continue reading “Bio Roundup: ASCO Digested, Juliet Unveiled, PTC Slated & More”

States Seek Slice of $7 Trillion Autonomous Vehicle Industry

As U.S. states and cites vie to capture some of the trillions of dollars of economic activity expected to flow from a shift to autonomous vehicles in the coming decades, Washington on Wednesday joined about two dozen states that have paved the way for testing driverless cars. Washington Gov. Jay Inslee directed relevant state agencies … Continue reading “States Seek Slice of $7 Trillion Autonomous Vehicle Industry”

ASCO Roundup: Checkpoint Combos, Tumor Profiling, Financial Toxicity

[Note: Ben Fidler coauthored this report.] The American Society of Clinical Oncology conference is wrapping up, and the closely watched medical meeting-slash-hype machine produced its usual array of data. There were a few big business-focused “horse race” stories—one company’s stumble was another company’s gain—but much of the news consisted of mid-trial updates that companies produce … Continue reading “ASCO Roundup: Checkpoint Combos, Tumor Profiling, Financial Toxicity”

Of Catfish & Fickle Lovers: Aste CEO Talks Online Dating’s Downsides

There are millions of fish in the sea, and dating apps have made it easier to quickly find and connect with a lot more of those would-be catches. But the ease of creating an online dating profile—and the lack of oversight by the companies running such services—means that users can, and often do, misrepresent themselves. … Continue reading “Of Catfish & Fickle Lovers: Aste CEO Talks Online Dating’s Downsides”

Precision Steps: Can Loxo Drug Help Broaden Use of Cancer DNA Tests?

When the FDA last week approved Merck’s cancer drug pembrolizuamb (Keytruda) for tumors with a specific genetic signature, regardless of what body part they originated in, it was a watershed moment for oncology and a victory for the concept of precision medicine. But Merck isn’t alone; others are following suit with similar plans, and their … Continue reading “Precision Steps: Can Loxo Drug Help Broaden Use of Cancer DNA Tests?”

SIGINT Wins Midway: Milestones of Innovation 13

In these days of internet disruptions of complex systems like medical care and even elections, our obsession with data security is swelling. We’re all too aware of how signals from myriad sources can help us construct patterns of human behavior and make plans to take advantage of that behavior. Although it may be no comfort … Continue reading “SIGINT Wins Midway: Milestones of Innovation 13”

Bio Roundup: ASCO Combo Frenzy, Maine’s Free DNA Tests, Sema4 & More

Over the next four days, the Second City will be the center of the biomedical world. The American Society of Clinical Oncology’s annual meeting in Chicago brings together thousands of researchers from across the globe to discuss the latest progress in the war against cancer. On tap this year: the crush of immunotherapy drug combinations, … Continue reading “Bio Roundup: ASCO Combo Frenzy, Maine’s Free DNA Tests, Sema4 & More”

Array Lands $31M in Licensing Deal with Japan’s Ono Pharma

Array BioPharma has agreed to license some rights to two of its clinical-stage cancer drugs to Ono Pharmaceutical, a deal that pays the Boulder, CO, biotech $31.6 million now and potentially more if those drugs hit key milestones. Ono, based in Osaka, Japan, gains development and commercialization rights in Japan and South Korea for binimetinib, … Continue reading “Array Lands $31M in Licensing Deal with Japan’s Ono Pharma”

Energy Leaders React to Trump’s Withdrawal From Paris Climate Accord

[Updated 6/2/17, 10:10 pm ET. See below.] President Donald Trump today announced the United States would withdraw from complying with what’s known as the Paris climate accord, a landmark international agreement to combat climate change. In December 2015, nearly all the countries in the world—195 of them—agreed to the pact, which aims to reduce emissions of … Continue reading “Energy Leaders React to Trump’s Withdrawal From Paris Climate Accord”

Countering Cybersecurity Turnover: 57 Companies That Do It Best

What does it take to keep highly skilled cybersecurity employees? Salary and benefits are table-stakes. Challenging work, ongoing training, an opportunity to advance without having to become a manager, and a talented peer group all help companies recruit and retain these sought-after “ninjas”—the individuals who can do what artificial intelligence security tools can’t. Research from … Continue reading “Countering Cybersecurity Turnover: 57 Companies That Do It Best”

In Maine, Making Cancer DNA Tests Free—And Asking Tough Questions

Has the era of genetic oncology arrived? Last week, the biomedical world took a notable step in that direction when the FDA said Merck’s drug pembrolizumab (Keytruda), already one of the world’s most successful cancer immunotherapies, could now treat any tumor with a particular genetic fingerprint. It was the first time a drug has been … Continue reading “In Maine, Making Cancer DNA Tests Free—And Asking Tough Questions”

Woodcock: New Approvals Show FDA Is Adapting to Precision Medicine

The randomized controlled trial has long been held up as the gold standard for testing new drugs. But the nation’s top drug evaluator, Janet Woodcock, believes they aren’t necessary for all new experimental treatments. Randomized trials are long, expensive to run, and ultimately produce limited answers, she said at a medical conference last week. The … Continue reading “Woodcock: New Approvals Show FDA Is Adapting to Precision Medicine”

On ASCO’s Eve, Experts Fret Over Backlash to Cancer Combo Frenzy

When thousands of cancer researchers from around the world gather in Chicago this weekend for the American Society of Clinical Oncology’s annual meeting, drugs that fight tumors by boosting a patient’s immune system will take center stage, as they have in previous years. But the stage is more crowded, as researchers have begun in earnest … Continue reading “On ASCO’s Eve, Experts Fret Over Backlash to Cancer Combo Frenzy”

Amid Budget Concerns, NIH Preps Beta Test for Precision Medicine Plan

An ambitious plan to recruit 1 million U.S. volunteers and amass a treasure trove of their health information will start next week with a “beta test” that health officials hope to eventually expand nationwide. National Institutes of Health director Francis Collins said Wednesday that the Precision Medicine Initiative will begin in Pittsburgh, where the agency … Continue reading “Amid Budget Concerns, NIH Preps Beta Test for Precision Medicine Plan”

Unconventional Partners, Like FDA, Can Drive Adoption of New Tech

We’ve heard it time and again. Drug development is too expensive, takes too long, and many drug candidates that show promise in preclinical trials end up failing because testing methods don’t predict how they will work in humans. Recently, new technologies have emerged that offer disruptive potential for steering the development of drugs in more … Continue reading “Unconventional Partners, Like FDA, Can Drive Adoption of New Tech”

Gottlieb Says FDA’s “Regulatory Tools” Can Help Fight Opioid Abuse

The FDA considers how safe and effective a new drug is before approving it. But for addictive opioid painkillers, which have triggered a massive public health crisis, should the agency also weigh the potential for the medication to be abused? That’s one of the questions that new FDA Commissioner Scott Gottlieb is posing as he … Continue reading “Gottlieb Says FDA’s “Regulatory Tools” Can Help Fight Opioid Abuse”

FDA Landmark Nod: Cancer Drug To Match Tumor Genes, Not Tissue Type

For many years, doctors and researchers have known that cancers in different parts of the body can share genetic abnormalities. For the first time, the FDA has approved a drug based on those abnormalities and not on the organ in which the cancer originated. It’s a moment that a lot of people in the cancer … Continue reading “FDA Landmark Nod: Cancer Drug To Match Tumor Genes, Not Tissue Type”

Trump’s Cybersecurity Czar Talks WannaCry, Industry Partnerships

The Trump administration’s plan for strengthening the nation’s cyber defenses is starting to come into focus. Rob Joyce, a special assistant to the president and the White House’s cybersecurity coordinator, spoke in Boston Monday at an event promoting the launch of CyberMA, a Massachusetts affiliate of the national CyberUSA initiative. CyberMA is a MassTLC-led group … Continue reading “Trump’s Cybersecurity Czar Talks WannaCry, Industry Partnerships”

Envision the Future: Request Your Invite to Our Napa Summit June 8-9

We are getting down to the wire—just two and a half weeks until Xconomy’s most unique, up close and personal event of the year: our sixth annual Napa Summit: The Xconomy Retreat on Technology, Jobs, and Growth. We have only about 20 spots left open, and a number of those will likely go fast. So … Continue reading “Envision the Future: Request Your Invite to Our Napa Summit June 8-9”

What’s Next for American Workers as Trade, Automation Roil Manufacturing?

When Donald Trump heralded Ford’s announcement earlier this year that it would invest $1.2 billion in its Michigan plants, it was seen by some as the fulfillment of campaign promises to “bring jobs back” and put America first. Last week, the other shoe dropped with reports that Ford will cut 10 percent of its global … Continue reading “What’s Next for American Workers as Trade, Automation Roil Manufacturing?”

Bio Roundup: Termeer Tribute, ASCO Peeks, Califf’s New Gigs & More

Exhausted by the nonstop drama in Washington, DC? Immerse yourself instead in this week’s biotech headlines. Let’s start with a tribute to a life sciences icon, then we’ll head around the Xconomy network with early news from the nation’s big yearly cancer meeting. There was also momentum onthe IPO front and new gigs for high-profile … Continue reading “Bio Roundup: Termeer Tribute, ASCO Peeks, Califf’s New Gigs & More”

The Reconfigurable Future of Healthcare

Data plays a more central role in healthcare than ever before. It won’t be long before every person’s genome is sequenced at birth, with follow-up sequencing done at regular intervals throughout life. Each genomic check-up would produce roughly 180 gigabytes of data that will need to be processed, analyzed, and stored. The promise of using … Continue reading “The Reconfigurable Future of Healthcare”

Distil’s Are You a Human Acquisition Is Big Win for Tech Community

Detroit’s nascent tech community got a significant validation today as Silicon Valley cybersecurity company Distil Networks announced it has acquired homegrown, Dan Gilbert-backed startup Are You a Human. The specific terms and the monetary value of the deal were not disclosed, but Distil says it plans to open a new office in Detroit as a … Continue reading “Distil’s Are You a Human Acquisition Is Big Win for Tech Community”

Figuring It Out: Addressing Practices That Impact Women in Technology

The Women’s March, New Tech Northwest’s annual “Women in Tech” event, and International Women’s Day are just a few of the recent events prompting important conversations around inequality in the tech industry. These discussions, while breakthroughs in many regards, are still just the beginning of real change. I’ve gathered a number of ideas for what … Continue reading “Figuring It Out: Addressing Practices That Impact Women in Technology”

Proofpoint Uncovers Second Cyberattack That Uses Stolen NSA Tools

Cybersecurity company Proofpoint, which helped slow the sweeping global ransomware attack WannaCry after it emerged Friday, has now discovered a much more insidious, profitable, and potentially widespread cyberattack called Adylkuzz. Adylkuzz doesn’t demand, as WannaCry does, that victims pay a ransom to retrieve their data. Adylkuzz makes no announcement when it quietly invades target computers. … Continue reading “Proofpoint Uncovers Second Cyberattack That Uses Stolen NSA Tools”

5 Takeaways From the WannaCry Ransomware Attack

This may be the incident that finally pushes ransomware into the mainstream—and also forces both organizations and malicious hackers to adapt their approaches when it comes to this type of attack. The “WannaCry” virus, which first hit companies and healthcare services on Friday, has infected some 300,000 computer systems in 150-odd countries. By exploiting a … Continue reading “5 Takeaways From the WannaCry Ransomware Attack”

Amid Comey Furor, Companies React to Trump’s Cybersecurity Order

On a day dominated by news about President Trump’s firing of FBI director James Comey, and its impact on the ongoing investigation of Russian hacking of the 2016 presidential election, two significant developments for the cybersecurity industry also emerged Thursday. First, President Trump signed an executive order laying out plans to shore up data security … Continue reading “Amid Comey Furor, Companies React to Trump’s Cybersecurity Order”

Bio Roundup: Big Apple Mo’, Checkpoint Yes and No, CAR-T Death & More

“New York, New York, it’s a hell of a town. The Bronx is up, but we’re Brooklyn down.” For all you old-school Brooklyn swingers out there, we’ll take a short break from the madness in the nation’s capital and start our roundup in the greatest city in the world. You might disagree if you’ve got … Continue reading “Bio Roundup: Big Apple Mo’, Checkpoint Yes and No, CAR-T Death & More”

Senate Vote Confirms Scott Gottlieb for FDA Commissioner

Scott Gottlieb will be the new FDA commissioner. The U.S. Senate voted 57 to 42 on Tuesday to confirm Gottlieb, a physician and venture capitalist, to lead the regulatory agency. He succeeds former FDA commissioner Robert Califf, who stepped down in January after President Donald Trump took office. Gottlieb is already familiar with the agency … Continue reading “Senate Vote Confirms Scott Gottlieb for FDA Commissioner”

Accera Appoints Judith Walker Chief Medical Officer

Accera, a clinical-stage biotech developing treatments for central nervous system disorders, has appointed Judith Walker to its chief medical officer position. Before joining Boulder, CO-based Accera, Walker was vice president of product development at QuintilesIMS (NYSE: [[ticker:Q]]), where her responsibilities included neurology and pain drugs. Walker’s experience also includes posts at Teva Pharmaceutical (NYSE: [[ticker:TEVA]]) … Continue reading “Accera Appoints Judith Walker Chief Medical Officer”